CTLA4 and non-small cell lung carcinoma: The Checkmate 9LA study, published in Lancet Oncology in January 2021, showed superior efficacy and activity in naive advanced NSCLC non-oncogene addicted patients treated with nivolumab (anti-PD1) plus ipilimumab (anti-CTLA4) associated with two cycles of platinum doublet chemotherapy histology based on their subsequent maintenance compared to four cycles of standard chemotherapy and subsequent maintenance with pemetrexed in non-squamous histology.